Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Goldman Sachs Upgrades Emergent BioSolutions (EBS) to Buy
November 2, 2018 4:29 AM EDTGoldman Sachs analyst Dana Flanders upgraded Emergent BioSolutions (NYSE: EBS) from Neutral to Buy with a price target of $75.00 (from $60.00).
The analyst believes a premium valuation is warrant due to the company's "sticky and growing" base business which has high barriers to entry.... More
